Search
Oncolytics Biotech Inc
ONCYAdd to Watchlist
0.753USD
+0.000+0.04%
Close 07-31 16:00（ET）Quotes delayed by 15 min
87.48MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Oncolytics Biotech Inc is 7.67, ranking 276 out of 385 in the Biotechnology & Medical Research industry. The average price target is 5.25, with a high of 10.00 and a low of 3.00.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
6.438
Target Price
+666.37%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Oncolytics Biotech Inc
ONCY
6
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Oncolytics Biotech Inc's price target?
Analysts forecast that Oncolytics Biotech Inc's price target is USD 5.25, with the highest forecast at USD 10.00 and the lowest forecast at USD 3.00.
How have Oncolytics Biotech IncONCY's recent earnings per share performed?
The market expectation was USD -0.08, while Oncolytics Biotech IncONCY's earnings per share (EPS) for the previous quarter was USD -0.08. EPS for the next quarter is expected at USD -0.05.
What is the analyst rating for Oncolytics Biotech Inc?
Based on the ratings of Oncolytics Biotech Inc's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.